HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Zhou, H. Articles by Korth-Bradley, J. Search for Related Content PubMed PubMed Citation Articles by Zhou, H. Articles by Korth-Bradley, J. Social Bookmarking                   What's this?

Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin

From the Clinical Pharmacology Department, Wyeth Research, Collegeville, Pennsylvania (Dr. Zhou, Ms. Buckwalter, Dr. Korth-Bradley); Clinical Pharmacology Department, Wyeth Research, Paris, France (Dr. Patat, Ms. Parks); and Forenap-Pharma, Rouffach, France (Dr. Metzger).

Etanercept, a soluble recombinant human tumor necrosis factor receptor (TNFr) fusion protein, is effective and well tolerated in the treatment of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). The primary objective of this study was to investigate the potential pharmacokinetic and pharmacodynamic interaction between a single dose of R- and S-enantiomers of warfarin and multiple doses of etanercept after administration of warfarin and etanercept alone and together. In a nonrandomized, three-period study, 12 healthy male subjects received a single oral 25-mg dose of warfarin after an overnight fast, followed by twice-weekly 25-mg subcutaneous doses of etanercept for seven doses. The last dose of etanercept was administered concurrently with a second dose of warfarin. Serial blood samples for plasma warfarin concentration measurement and international normalized ratio (INR) assessment were collected before and up to 144 hours after dose administration. Serial blood samples for serum etanercept concentration measurement were collected before and up to 60 hours after the sixth dose and 264 hours after the seventh dose. Etanercept did not affect the pharmacokinetics and pharmacodynamics of warfarin. All ratios of maximum serum concentration (C_max) and area under the serum concentration versus time curve (AUC) for pharmacokinetics (R- and S-enantiomers of warfarin) and INR fell within the confidence interval of 0.8 to 1.25. Warfarin also did not cause a clinically significant alteration in the pharmacokinetics of etanercept. In conclusion, coadministration of etanercept and warfarin would not be expected to change the pharmacokinetics of either medication; therefore, no dosage adjustment is needed in cases in which warfarin and etanercept are coadministered.

Key Words: Drug interaction • etanercept • warfarin

Address for reprints: Honghui Zhou, PhD, FCP, Clinical Pharmacology, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Vets, J.-F. Rossignol, and A. S. Jackson Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin Am. J. Health Syst. Pharm., May 1, 2009; 66(9): 838 - 842. [Abstract] [Full Text] [PDF]

				I. Mahmood and M. D. Green Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies J. Clin. Pharmacol., December 1, 2007; 47(12): 1540 - 1554. [Abstract] [Full Text] [PDF]

				H. Oberwittler, A. Hirschfeld-Warneken, R. Wesch, H. Willerich, L. Teichert, K.-H. Lehr, R. Ding, W. E. Haefeli, and G. Mikus Significant Pharmacokinetic and Pharmacodynamic Interaction of Warfarin With the NO-Independent sGC Activator HMR1766 J. Clin. Pharmacol., January 1, 2007; 47(1): 70 - 77. [Abstract] [Full Text] [PDF]

				H. Zhou Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein J. Clin. Pharmacol., May 1, 2005; 45(5): 490 - 497. [Abstract] [Full Text] [PDF]

				H. Zhou, P. R. Mayer, J. Wajdula, and S. Fatenejad Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid Arthritis J. Clin. Pharmacol., November 1, 2004; 44(11): 1235 - 1243. [Abstract] [Full Text] [PDF]

				H. Zhou, V. Parks, A. Patat, F. Le Coz, D. Simcoe, and J. Korth-Bradley Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin J. Clin. Pharmacol., November 1, 2004; 44(11): 1244 - 1251. [Abstract] [Full Text] [PDF]